Defence Therapeutics (DTC) AI Stock Analysis

• Market Cap: $51.99M
• Dividend Yield: N/A
• Average Volume (3M): 43.01K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.18
• Revenue Growth: N/A
• EPS Growth: 71.24%
• Country: CA
• Employees: 5
• Sector: Healthcare
• Sector Strength: 60
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 54,725,370
• 10 Day Avg. Volume: 46,227
• 30 Day Avg. Volume: 43,008
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Defence Therapeutics faces significant financial challenges with no revenue and high losses. While recent corporate events show promise for strategic direction, the overall financial health and valuation are concerning. Technical indicators provide mixed signals with potential long-term recovery but weak near-term momentum.

Defence Therapeutics Business Overview & Revenue Model

Company Description

Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

How the Company Makes Money

Defence Therapeutics generates revenue through the development and commercialization of its proprietary Accum™ technology, which is licensed to pharmaceutical companies and research institutions. The company earns income from licensing agreements, research and development collaborations, and potentially milestone payments and royalties from partners that utilize its technology in their therapeutic development. Additionally, Defence Therapeutics may receive funding from government grants or subsidies for their contribution to advancing healthcare solutions.

Defence Therapeutics Financial Statement Overview

Summary

Defence Therapeutics is struggling financially across all areas. With no revenue growth, significant losses, negative equity, and reliance on financing for cash, the company faces substantial financial challenges. Immediate strategic changes are necessary to improve financial health and sustainability.

Income Statement

Defence Therapeutics has faced consistent revenue challenges, with total revenue remaining at zero over the reported periods. The company shows significant negative EBIT, EBITDA, and net income, indicating a lack of profitability and efficiency. The absence of revenue growth and persistent losses are major concerns.

Balance Sheet

The company's financial stability is concerning with a negative stockholders' equity, indicating liabilities exceed assets. High leverage is evident with a total debt that significantly surpasses equity, posing a risk to financial health. The equity ratio is negative, further highlighting financial distress.

Cash Flow

Defence Therapeutics experiences negative operating and free cash flows, reflecting inadequate cash generation for operational needs and capital expenditures. The company relies on financing activities for cash inflow, which is unsustainable long-term. There is no visible growth in free cash flow.

Breakdown
Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
-90.92K	-13.82K	0.00	0.00	0.00
	EBIT
-12.66M	-6.48M	―	―	-673.18K
	EBITDA
-12.68M	-6.48M	0.00	-2.86M	-673.18K
	Net Income Common Stockholders
-13.19M	-6.76M	-7.34M	-2.86M	-673.18K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
56.55K	2.79M	506.70K	5.45M	1.87M
	Total Assets
477.75K	3.53M	719.67K	5.61M	1.91M
	Total Debt
1.75M	1.75M	0.00	0.00	0.00
	Net Debt
1.69M	-1.05M	-506.70K	-5.45M	-1.87M
	Total Liabilities
4.06M	1.97M	1.11M	122.26K	48.35K
	Stockholders Equity
-3.58M	1.57M	-387.56K	5.49M	1.86M
Cash Flow		Free Cash Flow
-4.49M	-7.72M	-6.04M	-2.29M	-178.85K
	Operating Cash Flow
-4.29M	-7.66M	-6.04M	-2.29M	-132.83K
	Investing Cash Flow
-203.24K	-65.80K	0.00	0.00	-46.02K
	Financing Cash Flow
1.76M	10.01M	1.10M	5.88M	2.04M

Defence Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.95
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DTC, the sentiment is Positive. The current price of 0.95 is above the 20-day moving average (MA) of 0.90, below the 50-day MA of 1.04, and above the 200-day MA of 0.78, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 50.63 is Neutral, neither overbought nor oversold. The STOCH value of 80.77 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:DTC.

Defence Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.24B	3.76	-41.88%	2.85%	17.01%	0.78%
DTC	30 Underperform	$51.99M	―	281.56%	―	―	71.24%

Defence Therapeutics Corporate Events

Defence Therapeutics Enhances Cancer Treatment with New Collaboration

Defence Therapeutics has announced a collaboration with Canadian Nuclear Laboratories to enhance the efficacy and safety of radio-immunoconjugate cancer therapies by combining its proprietary Accum® technology with Actinium-225. This partnership aims to improve the delivery and effectiveness of cancer-targeting antibodies by facilitating their escape from endosomes, thereby increasing their accumulation in the cell nucleus. The collaboration is a significant step in Defence’s mission to revolutionize cancer treatment and positions the company well within the growing global radiopharmaceutical market.

Spark’s Take on TSE:DTC Stock

According to Spark, TipRanks’ AI Analyst, TSE:DTC is a Underperform.

Defence Therapeutics faces significant financial challenges with no revenue and high losses. Recent corporate events bring some optimism by enhancing strategic direction and securing financing, but overall financial health and valuation remain serious concerns. Technical indicators show mixed signals, with potential long-term recovery, but near-term momentum is weak.

To see Spark’s full report on TSE:DTC stock, click here.

Defence Therapeutics Appoints Dr. Elias Theodorou as COO to Boost US Market Presence

Defence Therapeutics has appointed Dr. Elias Theodorou as Chief Operating Officer, marking a significant milestone for the company. Dr. Theodorou, a molecular biologist with extensive experience in cancer research and gene delivery, will be based in Boston and is expected to accelerate Defence’s development programs and strengthen its position in the US market. His expertise aligns with Defence’s mission to advance its Accum® technology, potentially catalyzing the company’s platform in the fields of ADCs and radioimmunoconjugates. The appointment is seen as a strategic move to leverage the US biotech ecosystem and forge partnerships that could drive the next wave of cancer therapeutics.